Concanamycin A (high purity)
85 CHF CHF 85.00
BVT-0237-C02525 µgCHF 85.00
BVT-0237-C100100 µgCHF 145.00
BVT-0237-M0011 mgCHF 430.00
BVT-0237-M0055 mgCHF 1'620.00
|Synonyms||Folimycin; Antibiotic TAN 1323B; Antibiotic X4357B|
|Source/Host Chemicals||Isolated from Streptomyces sp.|
|Purity Chemicals||≥98% (HPLC)|
|Appearance||White to off-white solid.|
|Solubility||Soluble in methanol, DMSO or acetonitrile; insoluble in water.|
|Identity||Determined by 1H-NMR.|
|Declaration||Manufactured by BioViotica.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Protect from light when in solution.|
Stable for at least 1 year after receipt when stored at -20°C.
After reconstitution protect from light at -20°C.
|Product Specification Sheet|
- More potent and specific H+-ATPase inhibitor than bafilomycin A1 (Prod. No. BVT-0252).
- Inhibits acidification of organelles such as lysosomes and the Golgi apparatus.
- Inhibitor of autophagic degradation by rising lysosomal pH and thus inactivating the lysosomal acid hydrolases.
- Blocks cell surface expression of viral glycoproteins without affecting their synthesis.
- Cytotoxic in a number of cell lines in a cell viability assay.
- Induces nitric oxide (NO) production.
- Concanamycin A enables the immune system to kill HIV-infected cells. Nef is an HIV-encoded accessory protein that enhances pathogenicity by down-regulating major histocompatibility class I (MHC-I) expression to evade killing by cytotoxic T lymphocytes (CTLs). Concanamycin A has been identified as potent inhibitor of Nef that restores MHC-I and enhances the clearance of HIV-infected primary cells by cytotoxic T lymphocytes. Concanamycin A counteracts Nef from diverse clades of HIV targeting multiple allotypes of MHC-I, indicating the potential for broad therapeutic utility.
- Isolation and characterization of concanamycins A, B and C: H. Kinashi, et al.; J. Antibiot. 37, 1333 (1984)
- Folimycin (concanamycin A), a specific inhibitor of V-ATPase, blocks intracellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the Golgi apparatus: M. Muroi, et al.; Cell Struct. Funct. 18, 139 (1993)
- Folimycin (concanamycin A), an inhibitor of V-type H(+)-ATPase, blocks cell-surface expression of virus-envelope glycoproteins: M. Muroi, et al.; BBRC 193, 999 (1993)
- Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases: S. Drose, et al.; Biochemistry 32, 3902 (1993)
- Involvement of the vacuolar H(+)-ATPases in the secretory pathway of HepG2 cells: M. Yilla, et al.; J. Biol. Chem. 268, 19092 (1993)
- Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells: F.J. Sharom, et al.; Biochem. J. 308 (Pt2), 381 (1995)
- Specific inhibitors of vacuolar type H(+)-ATPases induce apoptotic cell death: T. Nishihara, et al.; BBRC 212, 255 (1995)
- Concanamycin A, the specific inhibitor of V-ATPases, binds to the V(o) subunit c: M. Huss, et al.; J. Biol. Chem. 277, 40544 (2002)
- Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells: J. Hong, et al.; J. Pharmacol. Exp. Ther. 319, 672 (2006)
- Degradation of oxidized proteins by autophagy during oxidative stress in Arabidopsis: Y. Xiong, et al.; Plant Physiol. 143, 291 (2007)
- Inhibitors of the V0 subunit of the vacuolar H+-ATPase prevent segregation of lysosomal- and secretory-pathway proteins: J.A. Sobota, et al.; J. Cell Sci. 122, 3542 (2009)
- Inhibitors of V-ATPase: old and new players: M. Huss, et al.; J. Exp. Biol. 212, 341 (2009)
- Increased production of reactive oxygen species by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A in RAW 264 cells: A. Yokomakura, et al.; J. Toxicol. Sci. 37, 1045 (2012)
- Inhibition of vacuolar ATPase attenuates the TRAIL-induced activation of caspase-8 and modulates the trafficking of TRAIL receptosomes: V. Horova, et al.; FEBS J. 280, 3436 (2013)
- Estimating the rotation rate in the vacuolar proton-ATPase in native yeast vacuolar membranes: Z. Ferencz, et al.; Eur. Biophys. J. 42, 147 (2013)
- Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion: V. Michel, et al.; Int. J. Cancer 132, E1 (2013)
- Loss of vacuolar H+-ATPase activity in organelles signals ubiquitination and endocytosis of the yeast plasma membrane proton pump Pma1p: A. M. Smardon & P. M. Kane; J. Biol. Chem. 289, 32316 (2014)
- Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells: H. Jin, et al.; Toxicol. Appl. Pharm. 278, 17 (2015)
- Appropriate vacuolar acidification in Saccharomyces cerevisiae is associated with efficient high sugar fermentation: T.D. Nguyen, et al.; Food Microbiology 70, 262 (2018)
- Concanamycin A counteracts HIV-1 Nef to enhance immune clearance of infected primary cells by cytotoxic T lymphocytes: M.M. Painter, et al.; PNAS 117, 23835 (2020)
- The V-type ATPase enhances photosynthesis in marine phytoplankton and further links phagocytosis to symbiogenesis: D.P. Yee, et al.; Curr. Biol. in press (2023)